February 16, 2017 / 9:16 PM / in 8 months

BRIEF-Cytokinetics Q4 EPS $0.16

Feb 16 (Reuters) - Cytokinetics Inc

* Cytokinetics, inc. Reports fourth quarter 2016 financial results

* Q4 revenue $33.1 million versus $9.8 million

* Q4 revenue view $16.3 million -- Thomson Reuters I/B/E/S

* Q4 earnings per share $0.16

* Q4 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

* Cytokinetics inc sees anticipates 2017 cash revenue will be in range of $21 to $23 million

* Cytokinetics inc -expect to continue to enroll patients who complete vitality-als into vigor-als, an open-label extension trial throughout 2017

* Cytokinetics inc -expect to begin a phase 2 clinical trial of ck-2127107 in patients with als in mid-2017

* Cytokinetics inc -expect astellas to begin a phase 1b clinical trial of ck-2127107 in elderly patients with limited mobility in 1h 2017

* Cytokinetics inc -expect data from a phase 2 clinical trial of omecamtiv mecarbil in japanese patients with chronic heart failure in q3 2017

* Cytokinetics inc sees 2017 cash research and development expenses will be in range of $108 to $112 million, and cash g&a expenses will be in range of $30 to $32 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below